Key facts
- It has raised $2.7M; the latest was Early Stage VC ($700K) in Nov 2025.
- Notable investors include Tech Incubator Program for Startup, FuturePlay.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for OncoLab
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoLab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoLab
Operator of a biotech company intended to develop next-generation immuno-oncology therapies for hard-to-treat cancers. The company's therapeutic platform is based on antibody-conjugated nanogels with enhanced drug delivery and immune checkpoint inhibition, enabling customers to access more effective, sustainable and targeted cancer treatments.
- Sector
- Healthcare
- HQ
- Cheongju, South Korea
- Founded
- 2024
- Employees
- 7
- Website
- oncolab.co.kr/
- Ownership
- Privately Held (backing)
OncoLab doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoLab shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoLab in its N-PORT filings yet. We sweep new filings monthly.